The effect of rosuvastatin and atorvastatin on erectile dysfunction in hypercholesterolaemic patients

Kardiologia Polska

Volumn 72, Issue 3, 2014, Pages 275-279

  Nurkalem, Zekeriya ^a   Yildirimtürk, Özlem ^a   Özcan, Kazim Serhan ^a   Kul, Şeref ^b   Çanga, Yiǧit ^a   Satilmiş, Seçkin ^a   Bozbeyoǧlu, Emrah ^a   Kaya, Cevdet ^c  

^a Siyami Ersek Cardiovascular Training and Research Hospital   (Turkey)

^b BEZMIALEM VAKIF UNIVERSITY   (Turkey)

^c GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

Author keywords

Atherosclerosis; Erectile dysfunction; Hypercholesterolaemia; Statin

Indexed keywords

ATORVASTATIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ADULT; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; ERECTILE DYSFUNCTION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; INTERNATIONAL INDEX OF ERECTILE FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; CHEMICALLY INDUCED;

ADULT; ANTICHOLESTEREMIC AGENTS; ATORVASTATIN CALCIUM; ERECTILE DYSFUNCTION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; ROSUVASTATIN CALCIUM;

EID: 84897141318     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: 10.5603/KP.a2013.0287     Document Type: Article

References (22)

1. Feldman HA, Goldstein I, Hatzicchristou DG et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol, 1994; 151: 54-61. (Pubitemid 24046934)
2. Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart, 2003; 89: 251-253.
3. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trails of statin. Lancet, 2005; 366: 1267-1278.
4. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature, 1990; 343: 425-430.
5. Solomon H, Samarasinghe YP, Feher MD et al. Erectile dysfunction and statin treatment in high cardiovascular risk patients. Int J Clin Pract, 2006; 60: 141-145. (Pubitemid 43740490)
6. Hattori H, Nakanishi N, Kasai K. Statin enhances cytokine mediated induction of nitric oxide synthesis in vascular smooth muscle cells. Cardiovasc Res, 2002; 54: 649-658. (Pubitemid 34595424)
7. Tsunekawa T, Hayashi T, Kano H et al. Cerivastatin, a hydroxymethylglutharylcoemzyme a reductase inhibitör, improves endothelal function in elderly diabetic patients within 3 days. Circulation, 2001; 104: 376-379. (Pubitemid 32678263)
8. Rosen RC, Cappellieri JC, Smith MD et al. Development and evaluation of an abriged 5-item version of the International Index of Erectile Dysfunction (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res, 1999; 11: 319-326. (Pubitemid 30052683)
9. Miner M, Billups KL. Erectile dysfunction and dyslipidemia: relevance and role of phosphodiesterase type-5 inhibitors and statins. J Sex Med, 2008; 5: 1066-1078. (Pubitemid 351618019)
10. Aronow WS, Frishman WH. Management of hypercholesterolemia in older persons fort he prevention of cardiovascular disease. Cardiol Rev, 2010; 18: 132-140.
11. Buhaescu I, Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem, 2007; 40: 575-584. (Pubitemid 46829082)
12. Mol MJ, Stalenhoef AF, Stuyt PM et al. Effects of inhibition of cholesterol synthesis by simvastatin on the production of adrenocortical steroid hormones and ACTH. Clin Endocrinol (Oxf), 1989; 31: 679-689. (Pubitemid 20014110)
13. Hyyppa MT, Kronholm E, Virtanen A et al. Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men? A randomized double-blind trial. Psychoneuroendocrinology, 2003; 28: 181-194. (Pubitemid 36044077)
14. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol, 2005; 45: 89-118. (Pubitemid 40261799)
15. Davignon J. Atherosclerosis: evolving vascular biology and clinical beneficial cardiovascular pleiotropic effects of statins. Circulation, 2004; 109: III-39-III-43.
16. Gokkaya SC, Ozden C, Ozdal OL et al. Effect of correcting serum cholesterol levels on erectile function in patients with vasculogenic erectile dysfunction. Scand J Urol Nephrol, 2008; 42: 437-440.
17. Morelli A, Chavalmane AK, Filippi S et al. Atorvastatin ameliorates sildenafil-induced penile erections in experimental diabetes by inhibiting diabetes-induced RhoA/Rho-kinase signalling hyperactivation. J Sex Med, 2009; 6: 91-106.
18. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol, 2005; 19: 117-125. (Pubitemid 40204354)
19. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol, 2005; 45: 89-118. (Pubitemid 40261799)
20. Corona G, Boddi V, Balercia G et al. The effect of statin therapy on testosterone levels in subjects consulting for erectile dysfunction. J Sex Med, 2010; 7: 1547-1556.
21. Sakamoto H, Kurosawa K, Sudou N, et al. Impact of aging on penile hemodynamics in men responding normally to prostaglandin injection: a power Doppler study. Int J Urol, 2005; 12: 745-750. (Pubitemid 41743358)
22. Moemen MN, Hamed HA, Kamel II et al. Clinical and sonographic assessment of the side effects of intracavernous injection of vasoactive substances. Int J Impot Res, 2004; 16: 143-145. (Pubitemid 38579459)